Neurofibromatosis Treatment Global Market Report 2024

Description

“Neurofibromatosis Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurofibromatosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurofibromatosis treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The neurofibromatosis treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Type: Neurofibromatosis 1 (NF1); Neurofibromatosis 2 (NF2); Schwannomatosis
2) By Treatment: Medications; Surgery; Radiation Therapy; Other Treatments
3) By End-Users: Hospitals; Clinics; Other End Users
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Treatment for neurofibromatosis addresses a genetic condition that leads to the growth of tumors on nerve tissue, which can emerge anywhere in the body, including the brain, spinal cord, and nerves. Its purpose is to effectively manage symptoms, slow down the progression of the disease, and mitigate potential complications.

Neurofibromatosis treatment encompasses approaches tailored for neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis. Neurofibromatosis type 1 (NF1) is a hereditary disorder characterized by the development of tumors on nerves throughout the body. Various treatment modalities such as medications, surgical interventions, radiation therapy, and other specialized approaches are utilized by a range of end-users, including hospitals, clinics, and other medical facilities.

The neurofibromatosis treatment market research report is one of a series of new reports from The Business Research Company that provides neurofibromatosis treatment market statistics, including neurofibromatosis treatment industry global market size, regional shares, competitors with a neurofibromatosis treatment market share, detailed neurofibromatosis treatment market segments, market trends and opportunities and any further data you may need to thrive in the neurofibromatosis treatment industry. This neurofibromatosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neurofibromatosis treatment market size has grown rapidly in recent years. It will grow from $11.41 billion in 2023 to $13.09 billion in 2024 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to aging population, advancements in ophthalmology, patient-centered care, global healthcare access.

The neurofibromatosis treatment market size is expected to see rapid growth in the next few years. It will grow to $21.58 billion in 2028 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to research and drug development, telemedicine and remote monitoring, patient education and support, reimbursement policies. Major trends in the forecast period include vision rehabilitation services, collaborative care models, data analytics and ai, optic nerve prostheses and implants.

The escalating healthcare expenditure is poised to be a significant driver of growth in the neurofibromatosis treatment market. Healthcare infrastructure encompasses all expenses associated with medical care, preventive measures, public health initiatives, rehabilitation, community health efforts, and health research. Given the nature of neurofibromatosis treatment, which involves various medical procedures like surgeries, biopsies, and advanced imaging tests (MRI and CT scans), adequate funding through healthcare expenditure is crucial. This funding also supports essential healthcare services, including specialized neurofibromatosis treatment. For instance, as per the 2021-2030 National Health Expenditure (NHE) report released by the Centers for Medicare & Medicaid Services, a US-based federal agency, it was projected that national health spending would experience an average annual increase of 5.1% from 2021 to 2030, reaching an approximate total of $6.8 trillion by 2030. Furthermore, within the same period, Medicare expenditures are anticipated to grow at an annual rate of 7.2%, while Medicaid spending is forecasted to increase at a yearly rate of 5.6%. Consequently, the surge in healthcare expenditure is a driving force behind the expansion of the neurofibromatosis treatment market.

The surge in healthcare expenditure is anticipated to be a driving force behind the growth of the neurofibromatosis treatment market in the foreseeable future. Healthcare infrastructure encompasses all costs associated with medical care, preventive measures, public health initiatives, rehabilitation, community health activities, and health research. The rise in healthcare spending is expected to enhance patient access to neurofibromatosis treatment options, thereby contributing to the effective management of the condition. For instance, as reported in the 2021-2030 National Health Expenditure (NHE) report by the Centers for Medicare & Medicaid Services, a US-based federal agency, it is projected that between 2021 and 2030, national health spending will experience an average annual increase of 5.1%, reaching an estimated total of nearly $6.8 trillion. Furthermore, during the same period, Medicare spending is projected to increase at a 7.2% annual rate, while Medicaid spending is anticipated to grow at a 5.6% annual pace. This substantial rise in healthcare expenditure is a driving factor in the expansion of the neurofibromatosis treatment market.

The adoption of poor diets is anticipated to impede the growth of the neurofibromatosis treatment market in the foreseeable future. Individuals diagnosed with neurofibromatosis type 1 tend to follow unhealthy dietary patterns characterized by a deficiency in essential nutrients like fiber, vitamins, and minerals, while exhibiting high consumption of sodium and fat. This dietary imbalance may negatively impact the overall health and treatment outcomes of neurofibromatosis patients. For instance, as per the 2022 Food and Health Survey conducted by the International Food Information Council (IFIC), a US-based non-profit organization, approximately 73% of consumers reported snacking at least once a day in 2022, marking an increase from the 58% reported in 2021. This shift towards less nutritious snacking choices highlights the prevalence of poor dietary habits. Consequently, the adoption of inadequate diets stands as a restraining factor in the growth of the neurofibromatosis treatment market.

Major players in the neurofibromatosis treatment market are dedicated to advancing innovative drugs and securing regulatory approval to maintain their market standing. This emphasis on drug development holds the potential to expand the array of treatment options available for neurofibromatosis, ultimately providing patients with more precise and efficacious therapeutic choices. For instance, in June 2021, AstraZeneca PLC, a leading pharmaceutical and biotechnology company based in the UK, announced a significant milestone. The European Commission granted approval for Koselugo, marking it as the first medication sanctioned in the European Union for the treatment of neurofibromatosis type 1 and plexiform neurofibromas in children aged three and above. Koselugo is an oral medication designed to inhibit the MEK-1 enzyme, a crucial factor in cell growth and division. By taking this targeted approach, Koselugo effectively reduces tumor volume and provides relief from the associated pain of plexiform neurofibromas. The approval of Koselugo in the EU was based on compelling findings from the SPRINT Phase II trial, demonstrating its potential to diminish the size of plexiform neurofibromas and significantly enhance the overall quality of life for patients.

In October 2022, Pasithea Therapeutics, a prominent biotechnology company based in the US, completed the acquisition of AlloMek Therapeutics for $1.05 million. This strategic move is set to significantly enhance Pasithea Therapeutics' drug development efforts, with a specific focus on the Central Nervous System (CNS). AlloMek Therapeutics, a pharmaceutical company also based in the US, specializes in the development of treatments for a range of conditions including neurofibromatosis, congenital muscular disease, and catastrophic cardiomyopathy.

Major players in the neurofibromatosis treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Vertex Pharmaceuticals Inc., Dr. Reddy's Laboratories, BioMarin Pharmaceutical, Allergan, BeiGene Ltd., BioXcel Therapeutics Inc., Blueprint Medicines Corp., Genway BioTech, SpringWorks Therapeutics, LGM Pharma LLC, Biotechnica Pharma Global, Affymax Inc.

North America was the largest region in the neurofibromatosis treatment market in 2023. The regions covered in neurofibromatosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurofibromatosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurofibromatosis treatment market consists of revenues earned by entities by providing services such as stereotactic radiosurgery, genetic evaluation, physical therapy and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurofibromatosis treatment market also includes sales of drugs such as selumetinib, bevacizumab and tricyclic antidepressants. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12342

1. Executive Summary

2. Neurofibromatosis Treatment Market Characteristics

3. Neurofibromatosis Treatment Market Trends And Strategies

4. Neurofibromatosis Treatment Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Neurofibromatosis Treatment Market Size and Growth

5.1. Global Neurofibromatosis Treatment Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Neurofibromatosis Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Neurofibromatosis Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Neurofibromatosis Treatment Market Segmentation

6.1. Global Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Neurofibromatosis 1 (NF1)
Neurofibromatosis 2 (NF2)
Schwannomatosis
6.2. Global Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Medications
Surgery
Radiation Therapy
Other Treatments
6.3. Global Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Clinics
Other End Users

7. Neurofibromatosis Treatment Market Regional And Country Analysis

7.1. Global Neurofibromatosis Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Neurofibromatosis Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Neurofibromatosis Treatment Market

8.1. Asia-Pacific Neurofibromatosis Treatment Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Neurofibromatosis Treatment Market

9.1. China Neurofibromatosis Treatment Market Overview
9.2. China Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Neurofibromatosis Treatment Market

10.1. India Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Neurofibromatosis Treatment Market

11.1. Japan Neurofibromatosis Treatment Market Overview
11.2. Japan Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Neurofibromatosis Treatment Market

12.1. Australia Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Neurofibromatosis Treatment Market

13.1. Indonesia Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Neurofibromatosis Treatment Market

14.1. South Korea Neurofibromatosis Treatment Market Overview
14.2. South Korea Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Neurofibromatosis Treatment Market

15.1. Western Europe Neurofibromatosis Treatment Market Overview
15.2. Western Europe Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Neurofibromatosis Treatment Market

16.1. UK Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Neurofibromatosis Treatment Market

17.1. Germany Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Neurofibromatosis Treatment Market

18.1. France Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Neurofibromatosis Treatment Market

19.1. Italy Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Neurofibromatosis Treatment Market

20.1. Spain Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Neurofibromatosis Treatment Market

21.1. Eastern Europe Neurofibromatosis Treatment Market Overview
21.2. Eastern Europe Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Neurofibromatosis Treatment Market

22.1. Russia Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Neurofibromatosis Treatment Market

23.1. North America Neurofibromatosis Treatment Market Overview
23.2. North America Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Neurofibromatosis Treatment Market

24.1. USA Neurofibromatosis Treatment Market Overview
24.2. USA Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Neurofibromatosis Treatment Market

25.1. Canada Neurofibromatosis Treatment Market Overview
25.2. Canada Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Neurofibromatosis Treatment Market

26.1. South America Neurofibromatosis Treatment Market Overview
26.2. South America Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Neurofibromatosis Treatment Market

27.1. Brazil Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Neurofibromatosis Treatment Market

28.1. Middle East Neurofibromatosis Treatment Market Overview
28.2. Middle East Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Neurofibromatosis Treatment Market

29.1. Africa Neurofibromatosis Treatment Market Overview
29.2. Africa Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Neurofibromatosis Treatment Market Competitive Landscape And Company Profiles

30.1. Neurofibromatosis Treatment Market Competitive Landscape
30.2. Neurofibromatosis Treatment Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. F. Hoffmann-La Roche AG
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Merck & Co. Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. AbbVie Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Novartis AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Neurofibromatosis Treatment Market Other Major And Innovative Companies

31.1. Sanofi S.A.
31.2. Bristol-Myers Squibb Company
31.3. AstraZeneca plc
31.4. GSK PLC
31.5. Takeda Pharmaceutical Company Limited
31.6. Eli Lilly and Company
31.7. Gilead Sciences Inc.
31.8. Amgen Inc.
31.9. Vertex Pharmaceuticals Inc.
31.10. Dr. Reddy's Laboratories
31.11. BioMarin Pharmaceutical
31.12. Allergan
31.13. BeiGene Ltd.
31.14. BioXcel Therapeutics Inc.
31.15. Blueprint Medicines Corp.

32. Global Neurofibromatosis Treatment Market Competitive Benchmarking

33. Global Neurofibromatosis Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Neurofibromatosis Treatment Market

35. Neurofibromatosis Treatment Market Future Outlook and Potential Analysis

35.1 Neurofibromatosis Treatment Market In 2028 - Countries Offering Most New Opportunities
35.2 Neurofibromatosis Treatment Market In 2028 - Segments Offering Most New Opportunities
35.3 Neurofibromatosis Treatment Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer